OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma
Yoshifumi Kadono, Shohei Kawaguchi, Takahiro Nohara, et al.
Anticancer Research (2021) Vol. 41, Iss. 3, pp. 1599-1606
Open Access | Times Cited: 17
Yoshifumi Kadono, Shohei Kawaguchi, Takahiro Nohara, et al.
Anticancer Research (2021) Vol. 41, Iss. 3, pp. 1599-1606
Open Access | Times Cited: 17
Showing 17 citing articles:
Inflammatory Markers in Cancer Immunotherapy
Deepak Ravindranathan, Viraj A. Master, Mehmet Asım Bilen
Biology (2021) Vol. 10, Iss. 4, pp. 325-325
Open Access | Times Cited: 48
Deepak Ravindranathan, Viraj A. Master, Mehmet Asım Bilen
Biology (2021) Vol. 10, Iss. 4, pp. 325-325
Open Access | Times Cited: 48
Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
Fei Zheng, Qingju Meng, Lei Zhang, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 15
Fei Zheng, Qingju Meng, Lei Zhang, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 15
Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis
Takafumi Yanagisawa, Keiichiro Mori, Satoshi Katayama, et al.
International Journal of Clinical Oncology (2021) Vol. 27, Iss. 1, pp. 59-71
Open Access | Times Cited: 30
Takafumi Yanagisawa, Keiichiro Mori, Satoshi Katayama, et al.
International Journal of Clinical Oncology (2021) Vol. 27, Iss. 1, pp. 59-71
Open Access | Times Cited: 30
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
Jorge Esteban-Villarrubia, Javier Torres-Jiménez, Carolina Bueno-Bravo, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 566-566
Open Access | Times Cited: 13
Jorge Esteban-Villarrubia, Javier Torres-Jiménez, Carolina Bueno-Bravo, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 566-566
Open Access | Times Cited: 13
Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study
Y Taneda, Fumihiko Urabe, Naoki Uchida, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Y Taneda, Fumihiko Urabe, Naoki Uchida, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Significant association between systemic inflammation response index and prognosis in patients with urological malignancies
Wangbin Ma, Rongqiang Liu, Xinyi Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Wangbin Ma, Rongqiang Liu, Xinyi Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
Brie‐Anne Mannah, John J. Park, Su Yin Lim
International Journal of Cancer (2025)
Open Access
Brie‐Anne Mannah, John J. Park, Su Yin Lim
International Journal of Cancer (2025)
Open Access
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, et al.
Oral Oncology (2024) Vol. 151, pp. 106739-106739
Closed Access | Times Cited: 3
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, et al.
Oral Oncology (2024) Vol. 151, pp. 106739-106739
Closed Access | Times Cited: 3
Prognostic Role of Systemic Inflammation Indexes in Metastatic Urothelial Carcinoma Treated With Immunotherapy
Michele Dionese, Umberto Basso, Francesco Pierantoni, et al.
Future Science OA (2023) Vol. 9, Iss. 7
Open Access | Times Cited: 8
Michele Dionese, Umberto Basso, Francesco Pierantoni, et al.
Future Science OA (2023) Vol. 9, Iss. 7
Open Access | Times Cited: 8
Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma
Ryo Kurashina, Kiyohiro Ando, Masaharu Inoue, et al.
Cancer Diagnosis & Prognosis (2023) Vol. 3, Iss. 2, pp. 230-235
Open Access | Times Cited: 6
Ryo Kurashina, Kiyohiro Ando, Masaharu Inoue, et al.
Cancer Diagnosis & Prognosis (2023) Vol. 3, Iss. 2, pp. 230-235
Open Access | Times Cited: 6
Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab
Ikko Tomisaki, Mirii Harada, Kei Tokutsu, et al.
In Vivo (2021) Vol. 35, Iss. 6, pp. 3563-3568
Open Access | Times Cited: 12
Ikko Tomisaki, Mirii Harada, Kei Tokutsu, et al.
In Vivo (2021) Vol. 35, Iss. 6, pp. 3563-3568
Open Access | Times Cited: 12
A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs
Takashi Nagai, Taku Naiki, Yosuke Sugiyama, et al.
Translational Andrology and Urology (2023) Vol. 12, Iss. 5, pp. 790-801
Open Access | Times Cited: 4
Takashi Nagai, Taku Naiki, Yosuke Sugiyama, et al.
Translational Andrology and Urology (2023) Vol. 12, Iss. 5, pp. 790-801
Open Access | Times Cited: 4
Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review
Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, et al.
Japanese Journal of Clinical Oncology (2023) Vol. 54, Iss. 3, pp. 254-264
Closed Access | Times Cited: 4
Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, et al.
Japanese Journal of Clinical Oncology (2023) Vol. 54, Iss. 3, pp. 254-264
Closed Access | Times Cited: 4
Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis
Xiaobin Gu, Xiaodan Han, Yanli Shen, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 1
Xiaobin Gu, Xiaodan Han, Yanli Shen, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 1
Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients
Katsuhiro Ito, Yuki Kita, Takashi Kobayashi
International Journal of Urology (2022) Vol. 30, Iss. 9, pp. 696-703
Closed Access | Times Cited: 5
Katsuhiro Ito, Yuki Kita, Takashi Kobayashi
International Journal of Urology (2022) Vol. 30, Iss. 9, pp. 696-703
Closed Access | Times Cited: 5
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
Takashi Matsuki, Daisuke Kawakita, Hideaki Takahashi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Takashi Matsuki, Daisuke Kawakita, Hideaki Takahashi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors
Keita Kobayashi, Shigeru Sakano, Hiroaki Matsumoto, et al.
Japanese Journal of Clinical Oncology (2024)
Closed Access
Keita Kobayashi, Shigeru Sakano, Hiroaki Matsumoto, et al.
Japanese Journal of Clinical Oncology (2024)
Closed Access
Clinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma
Shohei Kawaguchi, Kouji Izumi, Renato Naito, et al.
Cancer Diagnosis & Prognosis (2021) Vol. 1, Iss. 5, pp. 459-461
Open Access
Shohei Kawaguchi, Kouji Izumi, Renato Naito, et al.
Cancer Diagnosis & Prognosis (2021) Vol. 1, Iss. 5, pp. 459-461
Open Access
